I don't agree with the NPAT projections above - the lowest NPAT in the past three years was $7.5m in FY19 and that was with an EBITDA of $11.6m, slightly higher than the $11.1m EBITDA for 1HY21 alone. Surely the doubling of this number for the full year should elevate NPAT to above $8m if not higher (FY20 NPAT was $9m on $15m EBITDA). All the share based payments, deferred considerations and earnout payments might muddy the water a bit but it is clear that growth has been great after FY20 with the acquisitions.
I don't agree with the NPAT projections above - the lowest NPAT...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACF (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.005(0.47%) |
Mkt cap ! $329.2M | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.09 | $1.07 | $192.9K | 179.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 22545 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 158611 | 6 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| ACF (ASX) Chart |